KLF6 depletion promotes NF-κB signaling in glioblastoma.

Dysregulation of the NF-κB transcription factor occurs in many cancer types. Krüppel-like family of transcription factors (KLFs) regulate the expression of genes involved in cell proliferation, differentiation and survival. Here, we report a new mechanism of NF-κB activation in glioblastoma through depletion of the KLF6 tumor suppressor. We show that KLF6 transactivates multiple genes negatively controlling the NF-κB pathway and consequently reduces NF-κB nuclear localization and downregulates NF-κB targets. Reconstitution of KLF6 attenuates their malignant phenotype and induces neural-like differentiation and senescence, consistent with NF-κB pathway inhibition. KLF6 is heterozygously deleted in 74.5% of the analyzed glioblastomas and predicts unfavorable patient prognosis suggesting that haploinsufficiency is a clinically relevant means of evading KLF6-dependent regulation of NF-κB. Together, our study identifies a new mechanism by which KLF6 regulates NF-κB signaling, and how this mechanism is circumvented in glioblastoma through KLF6 loss.

Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias.

Genomic studies have identified recurrent somatic mutations in acute leukemias. However, current murine models do not sufficiently encompass the genomic complexity of human leukemias. To develop preclinical models, we transplanted 160 samples from patients with acute leukemia (acute myeloid leukemia, mixed lineage leukemia, B-cell acute lymphoblastic leukemia, T-cell ALL) into immunodeficient mice. Of these, 119 engrafted with expected immunophenotype. Targeted sequencing of 374 genes and 265 frequently rearranged RNAs detected recurrent and novel genetic lesions in 48 paired primary tumor (PT) and patient-derived xenotransplant (PDX) samples. Overall, the frequencies of 274 somatic variant alleles correlated between PT and PDX samples, although the data were highly variable for variant alleles present at 0-10%. Seventeen percent of variant alleles were detected in either PT or PDX samples only. Based on variant allele frequency changes, 24 PT-PDX pairs were classified as concordant while the other 24 pairs showed various degree of clonal discordance. There was no correlation of clonal concordance with clinical parameters of diseases. Significantly more bone marrow samples than peripheral blood samples engrafted discordantly. These data demonstrate the utility of developing PDX banks for modeling human leukemia, and emphasize the importance of genomic profiling of PDX and patient samples to ensure concordance before performing mechanistic or therapeutic studies.

The effect of folic acid supplementation with ferrous sulfate on the linear and ponderal growth of children aged 6-24 months: a randomized controlled trial.

BACKGROUND/OBJECTIVES: Studies evaluating the effect of folic acid supplementation, either alone or in combination with iron, on the linear and ponderal growth of children are practically nonexistent. The aim of this study was to assess the effect of folic acid supplementation with ferrous sulfate on both linear growth and weight gain in anemic and nonanemic children attending Municipal Daycare Centers in Goiania, State of Goias, Brazil. SUBJECTS/METHODS: A double-blind, randomized, controlled trial was conducted on 188 children aged 6-24 months. The effects of ferrous sulfate and folic acid supplementation were evaluated using the analysis of variance procedure, based on a double factorial model with two factors of fixed effects (folic acid supplementation and ferrous sulfate supplementation), adjusted for initial weight. The level of significance was 0.05. RESULTS: The children who received folic acid supplementation showed greater weight gain than the monthly average weight gain of those not given the supplement (P=0.026). This effect was independent of the dose of ferrous sulfate (P for interaction=0.693). Folic acid supplementation increased the gain of weight-for-age Z-score when compared with the placebo group (P=0.018), independent of the dose of ferrous sulfate. CONCLUSION: Folic acid had no effect on linear growth. The use of folic acid supplementation increased the monthly average weight gain and the gain in weight-for-age Z-score compared with the placebo group. This effect was independent of the dose of ferrous sulfate.

Padronizaçäo da técnica de imunofixaçäo na detecçäo e identificaçäo de paraproteínas séricas / Standartization of immunofixation technique for detection and identification of seric paraproteins

O diagnóstico e seguimento das paraproteinemias requer a identificaçäo e tipagem de paraproteínas (PP). A imunoeletroforese (IEF) é o método comumente usado embora demorado e pouco sensível. A técnica de imunofixaçäo (IF) é superior por ser mais sensível, rápida e de fácil interpretaçäo, particularmente no reconhecimento de PP presentes em baixa concentraçäo no soro e/ou urina. Consiste de fase eletroforética, seguida de fixaçäo, quando o anti-soro é colocado sobre o gel, precipitando a proteína. Objetivo. Este estudo objetiva padronizar a técnica de IF e compará-la à IEF. Métodos. Foram estudados os soros de 28 pacientes, sendo 25 portadores de mieloma múltiplo e 3 com hipergamaglobulinemia policlonal, comparados com 6 indivíduos normais. Todos foram submetidos à eletroforese (EF) em gel de agarose, à IEF e à IF. Resultados. O principal problema na padronizaçäo da IF foi a determinaçäo da diluiçäo que estabelecesse proporçäo ideal entre antígeno e anticorpo. A concentraçäo sérica ideal da PP, neste estudo, variou de 28 a 35 g/dL. A PP foi detectada e caracterizada por ambas as técnicas em 21 (84 por cento) dos indivíduos e näo detectada por nenhuma delas em 2 (8 por cento). Em outros 2, somente a IF conseguiu identificar a PP. Näo houve banda monoclonal à EF e à IEF que näo fosse identificada pela IF. Conclusäo. Nossos resultados permitem concluir que a IF é mais sensível que a IEF e deve ser incorporada à rotina de diagnóstico

[Standardization of immunofixation technique for the detection and identification of serum paraproteins]. / Padronização da técnica de imunofixação na detecção e identificação de paraproteínas séricas.

Diagnosis and follow up of paraproteinaemias require identification and typing of paraproteins. Immunoelectrophoresis is the most commonly used method, though a lengthy one and with low sensitivity. Immunofixation is more sensitive, faster and of easier interpretation, specially when monoclonal proteins are present in low concentration in the serum and/or urine. Immunofixation includes two steps. The first is electrophoresis; the second is immunofixation of the separated antigen by use of antiserum. The latter step is accomplished by layering the antiserum over the agarose gel immediately after electrophoretic separation of the proteins resulting in antigen/antibody precipitation. PURPOSE--The objective of this study is to standardize the technique of immunofixation and compare it to immunoelectrophoresis. METHOD--The serum of 28 patients (25 with multiple myeloma and 3 with polyclonal hypergammaglobulinaemia) was analysed and compared to 6 normal subjects. All were submitted to electrophoresis on agarose gel, immunoelectrophoresis and immunofixation. RESULTS--Dilution of the serum to produce a concentration suitable for immunofixation is critical. In our study the correct paraprotein concentration was 28 to 35 g/dl. Both methods detected and identified the paraprotein in 21 (84%) of the samples and in 2 (8%) it was not detected at all. In two of the samples, only immunofixation was able to detect and identify the paraprotein. There was not any monoclonal band observed either through the electrophoresis or immunoelectrophoresis that was not detected by the immunofixation. CONCLUSION--These results show that immunofixation is more sensitive than immunoelectrophoresis and therefore should be incorporated into diagnosis routine.

The lack of benefit of modest sodium restriction in the institutionalized elderly.

Modest restriction of sodium intake is commonly prescribed in hypertensive or fluid-retaining states in the elderly. In recent years this intervention is generally adjunctive to pharmacologic therapy. Its utility was tested by comparison of baseline serum urea nitrogen (BUN) and creatinine levels, weight, and mean blood pressure with these determinations six months after the daily dietary sodium intake was changed from 2 g to 4 g in 38 institutionalized elderly persons. No difference was discernible. In elderly persons in institutions, where diuretic therapy is common and the validity of diagnoses is not tested daily, the modest restriction of sodium intake may accomplish little more than reducing the palatability of food.

Laboratory evaluation of WBA 8119 as a rodenticide for use against warfarin-resistant and non-resistant rats and mice.

Feeding tests were carried out in the laboratory to evaluate WBA 8119 as a potential new rodenticide against wild common rats (Rattus norvegicus), ship rats (R. rattus) and house mice (Mus musculus). The results obtained are compared with data previously obtained for difenacoum, another member of the same series of 4-hydroxycoumarin anticoagulants. With warfarin-resistnat and non-resistant common rats, complete kills were obtained using a concentration of 0-0005% for 2 days, or 0-001% for 1 day: a 1-day test at 0-0005% killed 6 out of 10 and 17 out of 20 of the two types respectively. At 0-0005% complete kills of resistant ship rats were obtained after 2 days exposure and of resistant house mice after 1 day, but at 0-002% for 2 days there was some survival. Non-resistant ship rats and house mice were all killed after 2 days feeding on 0-002% bait. In 2-day palatability tests, R. norvegicus showed no significant aversion to the poison at 0-002% and 100% mortality was obtained. The poison was significantly unpalatable to R. rattus at 0-005% and to M. musculus at 0-005% and 0-002%, although with the last species these concentrations gave complete kills. It is concluded that WBA 8119 has greater activity than other known anticoagulants against the three commensal species examined. The laboratory results suggest that concentrations between 0-0005% and 0-002% would be suitable for field use against common rats, and between 0-002% and 0-005% for ship rats and house mice.

Laboratory evaluation of difenacoum as a rodenticide.

The efficacy of difenacoum as a new anticoagulant rodenticide was evaluated by blood coagulation studies and laboratory feeding tests using warfarin-resistant and non-resistant common rats (Rattus norvegicus), ship rats (R. rattus) and house mice (Mus musculus). Prothrombin assays indicated that the compound had as marked an activity with warfarin-resistant common rats as coumatetralyl had with non-resistant animals. Feeding tests confirmed that 0-005% would be a near-optimal concentration for field use, although there was some evidence of unpalatability. Results with ship rats and house mice were less favourable. Trials with enclosed colonies of warfarin-resistant mice confirmed the laboratory finding that although difenacoum was more effective than all other currently used anticoagulants, it was unlikely to give complete control. It is concluded that difenacoum is a valuable new rodenticide, especiaaly for controlling warfarin-resistant common rats.

Field trials of difenacoum against warfarin-resistant infestations of Rattus norvegicus.

The anticoagulant difenacoum was tested at two concentrations, 0-005 and 0-01%, in bait against warfarin-resistant rat infestations in farm buildings. Twelve out of the 14 treatments in which the lower concentration of the anticoagulant was used resulted in complete control. One of the remaining two treatments was probably also completely successful, but in the other a few rats, that were not eating the poisoned baits, were still active after 30 days of baiting. All six treatments done using the stronger concentration of poison were completely effective. Since it took as long to control infestations with 0.01% as with 0.005% difenacoum in treatments carried out under similar conditions, the lower concentration is recommended for use against warfarin-resistant rats.